Financial Data and Key Metrics Changes - Total revenue for Q4 2025 decreased by 14.8% to $7.7 million compared to $9.1 million in Q4 2024, primarily due to the expiration of Gamma Knife contracts and lower proton beam radiation therapy volumes [12] - For the full year 2025, total revenue was $28.1 million, slightly down from $28.3 million in 2024 [13] - Gross margin for Q4 2025 was approximately $906 thousand or 12%, down from 35% in Q4 2024, reflecting lower treatment volumes and a shift towards direct patient services [13] - Net loss attributable to the company improved to $631 thousand or $0.09 per diluted share, compared to a net loss of $1.6 million or $0.23 per diluted share in the prior year [13] - Adjusted EBITDA for the full year was $5.5 million, down from $8.9 million in 2024 [16] Business Line Data and Key Metrics Changes - Revenue from direct patient care services increased by 23.7% to $15.5 million, while leasing revenue declined to $12.6 million [14] - LINAC revenue increased by 35.4% to $11.5 million, while Gamma Knife revenue decreased by 5.5% to $9.2 million, and proton beam radiation therapy revenue declined by 26% to $7.4 million [14] - LINAC treatment sessions more than doubled to 28,147 in 2025, marking the first full year of operations for both Puebla and Rhode Island centers [14] Market Data and Key Metrics Changes - The international business remains a strong contributor, with successful operations in Puebla, Mexico, and leadership positions in Ecuador and Peru [10] - The company is developing a new center in Guadalajara, Mexico, expected to begin operations in 2026, which represents significant future opportunity [10] Company Strategy and Development Direction - The company is focused on strengthening health system partnerships, expanding clinical capabilities, and enhancing patient access to advanced cancer care [4] - A transition towards a direct patient care model is underway, which now represents the majority of revenue and provides a stable platform for long-term growth [4] - Future priorities include increasing treatment volumes, driving operational efficiencies, and expanding the footprint through disciplined development [11] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges in 2025, including physician turnover and reimbursement dynamics, but emphasized decisive actions taken to address these issues [5] - The company is optimistic about 2026, citing a strong foundation for future growth supported by partnerships and expanded clinical capacity [11] - Ongoing discussions with lenders regarding capital structure enhancements are constructive, aiming to support long-term growth initiatives [6] Other Important Information - The company ended 2025 with approximately $3.7 million in cash, down from $11.3 million at the end of 2024, primarily due to capital expenditures related to expansion [16] - Total debt at year-end was approximately $17.3 million, with certain financial covenants not met due to lower profitability and higher operating costs [17] Q&A Session Summary Question: Will the company be able to offset revenue declines from expired contracts by referring patients between centers in Rhode Island? - Management confirmed that leveraging infrastructure across a larger footprint is part of the strategy in Rhode Island [21] Question: What is the timeline for constructing the new facility in Rhode Island and staffing it? - The Bristol facility is expected to come online in late 2027, followed by the proton facility in 2028, with staffing initiatives starting several months in advance [22] Question: Why were the expired contracts not disclosed earlier? - Management explained that the expiration of contracts was previously mentioned, and the health systems opted to update their equipment independently [28][31] Question: Will the company be profitable in 2026? - Management refrained from speculating on profitability for 2026, emphasizing that foundational issues have been addressed [35] Question: Is the company constrained from buying back stock due to credit agreements? - Management indicated that the company has not been interested in a stock buyback program and that current lender conditions make it unlikely to change this stance [44]

Financial Data and Key Metrics Changes - In 2025, the company achieved record revenue of $66.6 million, a nearly 20% increase over 2024, with testing volume up over 11% and trailing 12-month ASP up over 7% [21][27][29] - Gross margin for 2025 was just over 58%, down from about 60% in 2024, reflecting ASP pressure experienced in the second half of the year [23][24] - Operating expenses for 2025 were $53 million, up about 13% compared to 2024, indicating early signs of scale in the business as revenue growth outpaced expense growth [24][25] Business Line Data and Key Metrics Changes - The company reset the volume run rate from approximately 30,000 tests in Q1 to over 35,000 tests in subsequent quarters, marking the highest Q4 testing volume in Exagen's history [11][21] - ASP at the end of 2025 was approximately $441, up from $411 at the start of the year, driven by new product enhancements and improved revenue cycle management [12][22] Market Data and Key Metrics Changes - The company expanded its sales force from 40 to 45 territories in 2025, with expectations for improved productivity from new sales representatives over time [12][21] - The Pharma Services segment generated $1.7 million in revenue in 2025, significantly up from roughly $100,000 in 2024, with a backlog value of over $4 million expected to be realized over the next 2-3 years [23] Company Strategy and Development Direction - The company aims to own the entire autoimmune diagnostics space, focusing on comprehensive care and innovation to address significant unmet needs in the market [6][18] - The strategy includes advancing adoption through an upgraded sales force, expanding ASP through revenue cycle optimizations, and driving innovation with a structured product cadence [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to achieve sustainable, profitable growth, with revenue expectations for 2026 set between $70 million to $73 million [18][27] - The company is focused on creating a foundation for innovation and evaluating select inorganic opportunities to support long-term growth [19][20] Other Important Information - The company has five promising assets in development and plans to launch one product each year to expand its addressable market opportunity [15][16] - The American College of Rheumatology has begun advocating for the company's products, which is expected to drive medical policy progress with payers [14][50] Q&A Session Summary Question: Why is it the right time to make investments despite profitability targets? - Management indicated that investments in the commercial organization and R&D are necessary for durable cash flow positivity, emphasizing the importance of achieving sustainable growth [32][35] Question: What is the commercialization target for the myositis product? - The company aims to have the myositis offering ready for the clinic by 2027, with ongoing internal feasibility studies and validation of assays [36][37] Question: What is the expected ASP for Q4 2026? - Management did not disclose specific ASP figures but indicated that they expect stabilization and incremental gains in the second half of 2026 [39][40] Question: How is the Northwell Health situation affecting volume growth? - Management views the Northwell situation as a one-time setback and has seen growth initiatives compensate for any lost volume [40][41] Question: What is the status of the local coverage determination for rheumatologic disease? - The company maintains regular contact with the team at MolDX regarding the draft LCD, which is expected to cover broader testing in rheumatologic conditions [76][77] Question: What are medical directors asking about during discussions? - Medical directors are interested in understanding the clinical impact of the company's tests on patient outcomes and are looking for contemporary data to support their decisions [80][81]

Financial Data and Key Metrics Changes - Revenue growth for Q4 2025 was 9%, with adjusted EBITDA net of NCI increasing by 10% and adjusted EPS rising by 20% compared to Q4 2024 [6][12] - For the full year 2025, revenue growth was 10%, adjusted EBITDA net of NCI increased by 15%, and adjusted EPS grew by 31% [6][12] - Net income attributable to UHS per diluted share for Q4 2025 was $7.06, with adjusted net income per diluted share at $5.88 [13][14] Business Line Data and Key Metrics Changes - In the acute care segment, same-facility net revenues increased by 6.9% in Q4 2025, with a 5.4% increase in revenue per adjusted admission [14][15] - The behavioral health segment saw same-facility net revenues increase by 7.2%, supported by a 5.6% increase in revenue per adjusted patient day [17] - Acute care same-facility EBITDA grew by 10.4% in Q4 2025, with EBITDA margin improving to 14.8% [16] Market Data and Key Metrics Changes - Acute care volumes were flat, impacted by softness in the Las Vegas market, but excluding this market, volumes would have increased by 1% [13][14] - Behavioral segment headcount grew by 3.1%, with total same-facility labor expense growth at 7.3% per adjusted day [17][18] Company Strategy and Development Direction - The company is focused on expanding inpatient capacity and enhancing outpatient services, with plans for new service locations and behavioral health projects [8][9] - Technology adoption is a priority, with AI being deployed to improve clinical outcomes and operational efficiency [10][11] - The company aims to sustain its leadership position by diversifying service offerings and payer mix in the behavioral health segment [9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about future growth, citing investments in people, facilities, and technology [12] - For 2026, the company expects revenue between $18.4 billion and $18.8 billion, with adjusted EBITDA net of NCI ranging from $2.64 billion to $2.79 billion [19][20] - The guidance includes assumptions about adverse impacts from health insurance exchange reductions and new California staffing regulations [21][22] Other Important Information - Cash generated from operating activities was $1.9 billion for 2025, down from $2.1 billion in 2024, affected by increased receivables and timing of Medicaid payments [18] - The company repurchased 4.65 million shares for $899 million in 2025, with $1.425 billion of repurchase authorization remaining [19] Q&A Session Summary Question: Guidance for 2026 volume growth and pricing assumptions - Management expects a 3%-4% pricing increase in acute care and 2%-3% in behavioral health, acknowledging a moderation in pricing growth [26][27] Question: Impact of AI on operating performance - Initial AI efforts focus on administrative efficiencies, with potential significant impacts on revenue and margins expected over time [28][29] Question: Acute care volume expectations and Nevada market performance - Surgical volume growth in 2025 was positive but lagged overall volume growth; Nevada's market growth was in line with the acute division despite challenges [34][35] Question: Exchange volume visibility and potential bad debt - A 25%-30% decline in exchange volumes is anticipated, with early reporting likely understating the actual decline [39][40] Question: California staffing requirements impact - New staffing regulations will require a different mix of staff, leading to upfront costs and potential short-term volume disruption [45][46] Question: Behavioral outpatient service demand - Outpatient services currently represent about 10% of behavioral segment revenue, with expectations for continued growth in 2026 [51][52] Question: Medicaid supplemental payment programs approval status - Florida's program is expected to be approved soon, while California's program faces more hurdles [70][71]

Core Insights - Nutex Health Inc. reported a significant financial turnaround for the fiscal year 2024, with total revenue increasing by 93.8% to $479.9 million compared to $247.6 million in 2023, and net income of $52.1 million compared to a net loss of $45.8 million in the previous year [6][14][17] - The company restated its financial results for the fourth quarter and the entire fiscal year 2024, leading to a net increase in liabilities by $13.4 million (2.9%) and a corresponding decrease in equity by the same amount (6.6%) [4][3] - Adjusted EBITDA for 2024 reached $124.1 million, marking a 1046.1% increase from $10.8 million in 2023, indicating strong operational performance [6][11][22] Financial Performance - Total revenue for the year ended December 31, 2024, was $479.9 million, a 93.8% increase from $247.6 million in 2023 [6][14] - Net income attributable to Nutex Health for 2024 was $52.1 million, compared to a net loss of $45.8 million in 2023 [6][14] - Diluted earnings per share decreased by $0.02 to $9.69 from $9.71, while basic earnings per share also decreased by $0.02 to $10.23 from $10.25 [4][6] Operational Highlights - Total visits at the Hospital Division increased to 168,388 for the year ended December 31, 2024, up 16.9% from 144,058 in 2023 [14] - Revenue from mature hospitals (opened prior to December 31, 2021) increased by 56.6% in 2024 compared to 2023 [14] - Operating income for 2024 was $130.7 million, a significant improvement from an operating loss of $31.8 million in 2023 [14][17] Adjustments and Restatements - The restatement included non-cash adjustments, which had no material effect on key metrics such as revenue, liquidity, and operating cash flow [4][3] - Stock-based compensation expense for the year was $16.6 million, compared to $2.8 million in 2023, with 99% attributed to one-time obligations for under-construction hospitals [14][6] - The company corrected the classification of certain liabilities and reclassified related-party accounts payable balances, impacting the balance sheet structure [7][4] Cash Flow and Liquidity - Net cash from operating activities for the year was $23.2 million, reflecting improved operational efficiency [14][6] - As of December 31, 2024, the company had total assets of $655.3 million, including cash and cash equivalents of $40.6 million [15][14] - The company reported a record high cash balance of $40.6 million, underscoring its financial strength [11][14]

Financial Data and Key Metrics Changes - Exagen reported Q3 2025 revenue of $17.2 million, marking the highest quarter in the company's history and a nearly 40% increase compared to Q3 2024 [19] - Year-to-date revenue grew by 19% to approximately $50 million, with a trailing twelve-month average selling price (ASP) up over 9% and volume up over 8% [20][19] - Gross margin for Q3 was just over 58%, a decrease of about 175 basis points from the previous year, but year-to-date gross margin was just over 59%, up about 60 basis points [23][24] Business Line Data and Key Metrics Changes - The Pharma and CRO business generated nearly $800,000 in revenue for Q3, bringing the year-to-date total to $1.2 million, a significant increase from $100,000 in 2024 [15][20] - Testing volume for CTD was up 15% from Q3 of last year, contributing to overall revenue growth despite ASP challenges [19] Market Data and Key Metrics Changes - The company expanded its sales territories from 42 to 45, with total ordering physicians and orders per clinician continuing to trend upward [12][19] - The launch of new biomarkers, including anti PAD4 antibodies, is expected to enhance the company's market position, although initial revenue impact is anticipated to be modest [5][10] Company Strategy and Development Direction - Exagen aims to innovate in the biomarker space for rheumatoid arthritis, with a focus on personalized patient care and improved treatment outcomes [9][10] - The company is committed to profitable growth and plans to continue expanding sales territories where opportunities exist [12][19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's trajectory, highlighting strong volume growth and the potential for ASP improvements despite current challenges [19][26] - The company remains focused on achieving positive cash flow and disciplined capital allocation to support growth initiatives [17][25] Other Important Information - The company expects to deliver between $65 million to $70 million in revenue for the year, with the potential to be cash flow positive at the high end of the range [17] - Exagen's balance sheet remains strong, with $35.7 million in cash and cash equivalents at the end of Q3, up from $30 million at the end of Q2 [27][28] Q&A Session Summary Question: Update on revenue per territory for Q3 - The revenue per territory was slightly below the previous record of $430,000 due to the addition of new territories, but growth is expected over time [30][32] Question: Incremental uplift to ASP from new RA markers - The company is gathering payment history for the new RA markers and expects a modest uplift compared to previous launches [33][34] Question: Strength of Pharma partnership with urine platform - The first statement of work related to the urine platform has been completed, with ongoing discussions for future projects [35][36] Question: ASP target of $500 - Management believes the $500 ASP target is still realistic, but timing is uncertain due to recent challenges with a high ASP direct bill account [40][44] Question: Volume growth and seasonal factors - Volume was up in Q3 relative to Q2, and October showed strong performance, although a slight step down is expected in Q4 due to holidays [48][50] Question: Strength of Pharma business and future potential - The Pharma services revenue is expected to continue growing, with opportunities in new disease areas and a strong pipeline [54][57] Question: Sales force expansion and rep productivity - It generally takes six to nine months for new sales reps to reach maturity, with recent hires showing strong early performance [63][66] Question: Denials related to new biomarkers - Higher denial rates are primarily related to new markers, with ongoing efforts to improve revenue cycle management and appeals processes [68][70]

Financial Data and Key Metrics Changes - In Q2 2025, the company reported sales of $2.2 billion, representing a 2.8% increase on an organic basis and a 3.9% increase on a reported basis compared to the prior year [27] - Gross margins improved to 56% of sales, an increase of 20 basis points over the prior year [30] - Earnings per share (EPS) for the quarter was $1.69, exceeding expectations due to sales outperformance and favorable margins [32] Business Line Data and Key Metrics Changes - The MedSurg segment generated $1.2 billion in sales, a 3.9% organic growth, driven by infection prevention and surgical solutions, which grew 5.9% [28] - The Advanced Wound Care business saw a growth of 0.8%, impacted by a product recall, but is expected to accelerate in the second half of the year [15][29] - The Dental Solutions segment achieved $338 million in sales, a 0.7% organic growth, supported by innovation in restorative products [29] - The Health Information Systems segment contributed $339 million in sales, a 3.2% organic growth, benefiting from strong customer retention [29] - The Purification and Filtration segment reported $252 million in sales, a 3.1% organic growth, led by bioprocessing filtration [30] Market Data and Key Metrics Changes - The company experienced a favorable foreign exchange impact of 110 basis points on reported growth [27] - The estimated tariff impact for 2025 has been reduced to $60 million to $80 million, down from $80 million to $100 million, easing pressure on gross and operating margins [34] Company Strategy and Development Direction - The company is focused on disciplined mergers and acquisitions (M&A) to enhance progress post the P and F transaction [9] - Five growth drivers have been identified to account for over 80% of long-term growth: negative pressure wound therapy, IV site management, sterilization assurance, core restoratives, and revenue cycle management [14] - The company aims to achieve sales growth of 4% to 5% and EPS growth at a 10% compound annual growth rate (CAGR) [37] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering growth and margin targets, raising sales growth and EPS guidance for the year [6] - The company is navigating an uncertain macro environment while making foundational changes to deliver on its long-range plan [24] - Management highlighted the importance of the ongoing ERP implementation and its expected positive impact on future cash flows [76] Other Important Information - The company has made significant progress in its separation from 3M, including exiting 35% of transition service agreements and completing corporate rebranding [26] - Solventum was recognized on the Fortune 500 list in its first year as a standalone company and named a best company to work for by U.S. News and World Report [22] Q&A Session Summary Question: What is driving the organic growth in the MedSurg business? - Management attributed growth to commercial restructuring, differentiated brands, and new product launches [42][44] Question: Can you provide clarity on the EPS bridge from last quarter to this quarter? - Management noted that the increase in EPS reflects strong performance and confidence in the second half, while managing various variables [50][52] Question: How do you view the underlying patient trends in the Dental Solutions business? - Management indicated that while there hasn't been a dramatic change, the focus remains on new products and specialized sales organization [98] Question: Can you elaborate on the partnership with Ensemble for autonomous coding? - Management explained that the partnership allows for integration of their technologies into Ensemble's accounts, enhancing efficiency and revenue capture [82][86]

Financial Data and Key Metrics Changes - The company reported net income attributable to UHS per diluted share of $5.43 for Q2 2025, with adjusted net income per diluted share at $5.35 after adjustments [4][6] - Adjusted admissions to acute care hospitals increased by 2% year-over-year, while surgical volumes decreased slightly [4] - Same facility net revenues in the acute care hospital segment increased by 5.7% compared to Q2 2024, excluding the impact of the insurance subsidiary [4] - Cash generated from operating activities decreased by $167 million to $909 million in Q2 2025 compared to $1,076 million in Q2 2024 [6] - The company spent $500 million on capital expenditures, with 25% allocated to new replacement facilities in California and Florida [6] Business Line Data and Key Metrics Changes - Same facility EBITDA increased by 10% in the acute care segment, driven by solid revenue and effective expense controls [5] - In the behavioral health segment, same facility net revenues increased by 5.4%, with a 4.2% increase in revenue per adjusted day [5] - Adjusted patient days in the behavioral health segment were up 1.2% compared to the prior year's second quarter [6] Market Data and Key Metrics Changes - The West Henderson Hospital, opened in late 2024, had a cannibalization impact on same facility volumes and revenues [5] - The company noted a slight decrease in surgical volumes, indicating potential market challenges [4] Company Strategy and Development Direction - The company is increasing its EPS guidance for 2025 by 7% to $20.50 per diluted share, driven by increased DPP reimbursement [10] - The company is focusing on outpatient growth in the behavioral segment, with plans to open 10-15 new outpatient facilities annually [42] - The company is developing new behavioral health hospitals in various locations, including Michigan and Pennsylvania, to expand its service offerings [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term prospects for the Cedar Hill Regional Medical Center despite initial startup challenges [11] - The company anticipates potential changes to Medicaid programs that could impact future revenues, with a projected reduction in net benefits starting in 2028 [8] - Management emphasized the ability to pivot and adapt to changes in the operating environment, drawing on past experiences during the pandemic [17][20] Other Important Information - The company repurchased approximately 1.9 million shares at a cost of $332 million since 2019, representing about 34% of outstanding shares [7] - The One Beautiful Bill Act includes significant changes to the Medicaid program, which may impact future revenues [8] Q&A Session Summary Question: Impact of Medicaid changes on EBITDA - Management confirmed the projected reduction of $360 million to $400 million in net benefits starting in 2028, with strategies to offset this through operational adjustments [15][17] Question: Behavioral health volume growth - Management noted that outpatient growth is a significant opportunity, with adjusted patient days growing faster than inpatient days [21][24] Question: Cedar Hill's startup losses - Management acknowledged $25 million in startup losses for Cedar Hill in Q2, with another $25 million expected in the second half of the year, but expressed optimism for future profitability [26][30] Question: Outpatient behavioral growth strategy - Management detailed plans to enhance outpatient services through step-down and step-in business models, aiming to capture a larger share of the outpatient market [38][42] Question: Labor market challenges - Management indicated that while wage inflation has slowed, staffing challenges persist, particularly in the behavioral segment [66][68] Question: DPP program updates - Management provided updates on ongoing discussions with CMS regarding the approval of DPP programs, emphasizing the potential for new programs despite legislative changes [70][72]

Financial Data and Key Metrics Changes - The company's revenue for Q1 2025 was $2.6 billion, up just under 1% as reported, but up 2.3% on a same-day basis compared to the prior year [16] - Adjusted net income for the quarter was $18 million or $0.23 per share, representing about 20% growth compared to $15 million or $0.19 per share last year [21] - Adjusted EBITDA grew 5% to $122 million versus $116 million reported during Q1 2024 [21] Business Line Data and Key Metrics Changes - Patient Direct revenue was $674 million, growing by 6% compared to Q1 2024, with a same-day growth of 7.3% [16] - The Products and Healthcare Services segment reported a decline of 0.8%, while on a same sales day basis, it grew 0.7% compared to the first quarter last year [18] - Operating income in the Patient Direct segment grew by 31%, contributing to a total operating income of $61 million, an improvement of about 7% versus Q1 2024 [20] Market Data and Key Metrics Changes - The company experienced continued growth in oxygen therapy, which began in Q4 2024, and expects growth throughout 2025 [17] - The Medical Distribution division saw good same-store sales, but lower glove prices and international sales offset this growth [18] Company Strategy and Development Direction - The company is actively engaged in discussions regarding the potential sale of its Products and Healthcare Services segment while continuing to run this segment with commitment [10] - Investments in revenue cycle management have led to record collection rates in Q1, with plans to extend these learnings to other divisions [9] - The company is implementing price increases in response to tariffs, effective in early June, while ensuring high-quality product delivery [13][14] Management's Comments on Operating Environment and Future Outlook - Management reaffirmed guidance for the year, expecting improving results in each subsequent quarter, with at least 70% of earnings and cash flow generated in the second half of the year [24] - The company remains bullish on the outlook for earnings and cash flow for the remainder of 2025 [25] Other Important Information - The anticipated annual exposure of current tariffs on products is estimated to be in the range of $100 million to $150 million [13] - The company has opened new state-of-the-art distribution centers to enhance efficiency and service [11] Q&A Session Summary Question: Can you discuss the discussions with customers regarding tariffs? - Management indicated that they are working with customers to identify alternatives and have increased inventory to mitigate tariff impacts [26][29] Question: What is the impact of foreign exchange on the business? - Management noted that while there was volatility in the dollar, they are comfortable with the guidance for the rest of the year regarding FX [31][33] Question: What is the split of tariff exposure between segments? - The majority of tariff exposure is in the Products and Healthcare Services segment, with very little exposure in the Patient Direct segment [40] Question: How is the RoTEK acquisition being accounted for in guidance? - The debt from the RoTEK acquisition will not appear on the balance sheet until the deal closes, and guidance will be updated accordingly [47][49] Question: What is the expected free cash flow for the year? - Management confirmed that they still expect to generate good free cash flow and use it to pay down debt [52]

Financial Data and Key Metrics Changes - The company's revenue for Q1 2025 was $2.6 billion, up just under 1% as reported, but up 2.3% on a same-day basis compared to the prior year [15] - Adjusted net income for the quarter was $18 million or $0.23 per share, representing about 20% growth compared to $15 million or $0.19 per share last year [19] - Adjusted EBITDA grew 5% to $122 million versus $116 million reported during Q1 2024 [19] Business Line Data and Key Metrics Changes - Patient Direct segment revenue was $674 million, growing by 6% compared to Q1 2024, with a same-day growth of 7.3% [15] - The Products and Healthcare Services segment reported a decline of 0.8%, while on a same sales day basis, it grew 0.7% compared to the first quarter last year [16] - Operating income for the Patient Direct segment grew by 31%, resulting in a 173 basis point expansion [6] Market Data and Key Metrics Changes - The Medical Distribution division saw continued growth in same-store sales, but lower glove prices and international sales offset this growth [16] - The company experienced a significant increase in proprietary product sales running through its distribution channel, a key strategic initiative [16] Company Strategy and Development Direction - The company is actively engaged in discussions regarding the potential sale of its Products and Healthcare Services segment while continuing to run this segment with commitment [9] - Investments in revenue cycle management have led to record collection rates in Q1, with plans to extend these learnings to other divisions [8] - The company is implementing price increases in response to tariffs, effective in early June, while ensuring high-quality product delivery [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's performance and reaffirmed guidance for the year, expecting improving results in each subsequent quarter [22] - The anticipated annual exposure of current tariffs on products is estimated to be between $100 million to $150 million, primarily affecting the Products and Healthcare Services segment [12][27] - Management noted that the first quarter typically marks the payment of incentive compensation, impacting cash flow, but expects significant improvement in cash flow for the remainder of the year [20] Other Important Information - The company opened new state-of-the-art distribution centers in Morgantown, West Virginia, and Sioux Falls, South Dakota, to enhance its distribution network [10] - The company is awaiting a final decision from regulators regarding the planned acquisition of RoTEK, expecting to close in the first half of 2025 [8] Q&A Session Summary Question: Can you discuss the discussions with customers regarding tariffs? - Management indicated that the tariff exposure is estimated between $100 million to $150 million, primarily from China and Thailand, and emphasized the need to work collaboratively with customers to address pricing adjustments [27][28] Question: How should we think about the FX impact progressing through the year? - Management noted that while there was volatility in the dollar, particularly in March, the situation has calmed, and they are comfortable with the guidance for the rest of the year regarding FX [31][32] Question: What is the split between the tariff exposure in the PNHS and PD segments? - Management clarified that virtually all tariff exposure is in the Products and Healthcare Services segment, with minimal exposure in the Patient Direct segment [40] Question: How is the RoTEK financing accounted for in guidance? - Management explained that none of the debt will appear on the balance sheet until the deal closes, and they will update guidance accordingly [47] Question: What happens if customers refuse price increases due to tariffs? - Management stated that they cannot sell products at a loss and will work with customers to find alternative products that are lower in cost [61][64]

Financial Data and Key Metrics Changes - Free cash flow reached record levels of $13.2 million, a year-over-year increase of nearly 250% [11] - Adjusted EBITDA rose to $24.1 million, a 56% increase year-over-year [11] - Net income surged to an all-time high of $7.9 million, compared to a net loss of $48.7 million in 2023 [39][43] - Revenue for Q4 2024 was $28.2 million, slightly down from $28.4 million in Q4 2023 [40] - GAAP net income for Q4 2024 was $3.3 million, compared to a net loss of $43.7 million in the same period last year [39] Business Line Data and Key Metrics Changes - Recurring technology-enabled business solution revenues were $24.8 million, essentially flat with Q4 2023 [40] - Non-recurring professional services revenues from medSR declined by approximately $400,000 [40] Market Data and Key Metrics Changes - The company anticipates revenue growth in the range of $111 million to $114 million for 2025, indicating a shift towards positive growth after previous declines [17] - Adjusted EBITDA for 2025 is projected to be between $26 million and $28 million [17] Company Strategy and Development Direction - The conversion of Series A preferred shares into common stock was a significant strategic move, aimed at optimizing the capital structure and enhancing shareholder value [13][15] - The company is focused on leveraging AI-driven solutions to improve provider efficiency and reduce administrative burdens [19] - CareCloud plans to expand specialty-based EHR solutions, targeting distinct needs of various medical specialties [34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving positive earnings per share for the first time since going public in 2014, reflecting the strength of the business transformation [11][18] - The company remains focused on strategic growth, efficiency, and expansion, with a commitment to innovation [17][35] Other Important Information - The company has fully repaid its Silicon Valley Bank line of credit and is now bank debt-free [38] - The removal of dividend obligations tied to preferred shares will free up additional resources for reinvestment into key growth areas [16] Q&A Session Summary Question: Revenue and EBITDA guidance for the year - Management indicated that they expect revenue growth in 2025, with a range of $111 million to $114 million, and adjusted EBITDA between $26 million and $28 million, reflecting a disciplined approach to cost management and innovation [54][55] Question: Insights on M&A pipeline and valuations - Management confirmed a re-entry into the acquisition market, focusing on smaller and mid-sized medical billing companies, with a disciplined approach to ensure any deals pursued are accretive and align with long-term objectives [60][64] Question: User base expansion and offerings - The user base is diversified, with a significant portion in primary care, and management sees opportunities to upsell various solutions to existing clients [70][72] Question: 2025 guidance and customer attrition - The 2025 revenue guidance does not factor in any material acquisitions, focusing instead on organic growth and small tuck-in opportunities [77][78] Question: Preferred stocks and dividends - Management clarified the Series A conversion details and ongoing obligations for the remaining preferred shares, indicating that dividends will continue to be paid on the outstanding shares [96][98]